Guardant Health Inc (GH) Stock AnalysisGHStock AnalysisGuardant Health Inc

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Guardant Health Inc is currently not a strong buy due to recent insider selling and a bearish market signal, despite a significant year-to-date price increase of 58.74%. The stock's current price is $161.50, which is below the analyst price target range of $130 to $200, indicating potential upside. However, the RSI is at 42.27, suggesting the stock is nearing oversold conditions, and the recent court ruling requiring a payment of $245.2 million poses a significant risk.

4 analysts cover GH: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 124.69.